Literature DB >> 27916496

Hyperlipidemia-Mediated Increased Advanced Lipoxidation End Products Formation, an Important Factor Associated with Decreased Erythrocyte Glucose-6-Phosphate Dehydrogenase Activity in Mild Nonproliferative Diabetic Retinopathy.

Subhadip Choudhuri1, Pijush Kanti Roy2, Bhaskar Mitra3, Susruta Sen4, Rajarshi Sarkar2, Mandrita Das2, Debashree Biswas5, Prithwijit Ghosh2, Ajoy Biswas2, Shaibal Chakraborty2, Lakshmi Kanta Mondal6.   

Abstract

OBJECTIVES: The present study aimed to evaluate the role of hyperlipidemia in increased formation of advanced lipoxidation end products (ALEs) and to evaluate whether there is any relationship between ALEs generation and erythrocyte glucose-6-phosphate dehydrogenase (G6PD) activity in cases of mild nonproliferative diabetic retinopathy (MNPDR).
METHODS: In this study, we enrolled 100 patients with type 2 diabetes and MNPDR, 100 subjects with type 2 diabetes but without retinopathy (DNR) and 90 normal individuals without diabetes as healthy controls (HCs). Erythrocyte nicotinamide dinucleotide phosphate (NADPH), G6PD activity, serum total cholesterol, low- and high-density lipoprotein (LDL, HDL) and triglyceride levels were determined by photometric assay. Serum malondialdehyde (MDA) protein adduct and hexanoyl-lysine (HEL) were measured by an enzyme-linked immunosorbent assay (ELISA).
RESULTS: A robust linear relationship was observed between MDA protein adduct and LDL or cholesterol or triglyceride levels, and HEL and LDL or cholesterol or triglyceride levels in subjects with MNPDR (p=0.0001). A significant inverse association was observed between erythrocyte G6PD activity and serum MDA protein adductor HEL levels in subjects with MNPDR (p=0.0001).
CONCLUSIONS: Hyperlipidemia is an important factor that is associated with increased ALEs formation in persons with MNPDR. Increased ALEs generation was associated with decreased G6PD activity and low NADPH levels in cases of MNPDR, suggesting their detrimental role in the occurrence of early NPDR.
Copyright © 2016 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  advanced lipoxidation end products (ALEs); diabetic retinopathy; glucose-6-phosphate dehydrogenase (G6PD); glucose-6-phosphate-déshydrogénase (G6PD); hyperlipidemia; hyperlipidémie; mild nonproliferative diabetic retinopathy (MNPDR); nicotinamide-adénine-dinucléotide phosphate réduit (NADPH); produits finaux de la lipoxidation avancée (ALE pour advanced lipoxidation end products); reduced nicotinamide adenine di nucleotide phosphate (NADPH); rétinopathie diabétique; rétinopathie diabétique non proliférante minime (RDNP minime)

Mesh:

Substances:

Year:  2016        PMID: 27916496     DOI: 10.1016/j.jcjd.2016.07.007

Source DB:  PubMed          Journal:  Can J Diabetes        ISSN: 1499-2671            Impact factor:   4.190


  4 in total

1.  Assessment of neuron-specific enolase, S100B and malondialdehyde levels in serum and vitreous of patients with proliferative diabetic retinopathy.

Authors:  Vusala Asadova; Zulfiye Gul; Rifat Levent Buyukuysal; Ozgur Yalcinbayir
Journal:  Int Ophthalmol       Date:  2019-09-30       Impact factor: 2.031

2.  Do different lipid components accelerate the pathogenesis and severity of Diabetic Retinopathy?

Authors:  Lakshmi Kanta Mondal; Subhasish Pramanik; Subhankar Chowdhury; Chiranjit Bose; Debgopal Bera; Ayindrila Saha; Koena Bhattacharjee
Journal:  Int J Retina Vitreous       Date:  2022-06-11

3.  N-Acetylcysteine protects against cobalt chloride-induced endothelial dysfunction by enhancing glucose-6-phosphate dehydrogenase activity.

Authors:  Chen Yang; Xiaofang Zhang; Xilin Ge; Chunmei He; Suhuan Liu; Shuyu Yang; Caoxin Huang
Journal:  FEBS Open Bio       Date:  2022-06-20       Impact factor: 2.792

Review 4.  Advanced Glycation End Products in the Pathogenesis of Psoriasis.

Authors:  Anastasia Papagrigoraki; Martina Maurelli; Micol Del Giglio; Paolo Gisondi; Giampiero Girolomoni
Journal:  Int J Mol Sci       Date:  2017-11-20       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.